Latest News and Press Releases
Want to stay updated on the latest news?
-
MONROE TOWNSHIP, N.J., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (NASDAQ: OPTT), a leader in innovative and cost-effective ocean energy solutions, will release its results for...
-
-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo ---- Company’s studies also show CCR4 inhibition...
-
GRAND CAYMAN, Cayman Islands, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Ocean Rig UDW Inc. (NASDAQ:ORIG), (“Ocean Rig” or the “Company”), an international contractor of offshore deepwater drilling services,...
-
PALO ALTO, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- HP (NYSE: HPQ) Fiscal 2018 GAAP diluted net earnings per share (“EPS”) of $3.26, above the previously provided outlook of $2.82 to $2.85 per...
-
SANTA CLARA, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), a leading developer of low-power and high-resolution human and computer vision solutions, today announced...
-
NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Presidio, Inc. (NASDAQ:PSDO) (together with its subsidiaries, “Presidio” or the “Company”), a leading North American IT solutions provider delivering...
-
NESS ZIONA, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
-
CAMBRIDGE, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which...
-
NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- MongoDB, Inc. (NASDAQ: MDB), the leading modern, general purpose database platform, today announced that its Chief Financial Officer, Michael Gordon, will...
-
- Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease Activity within four weeks of starting PRN1008 - - Demonstrated sustained clinical efficacy at 12 weeks of...